

## Cosentyx Rheum - Digital dosing schedule - HCP

[Prescribing information](#)

Image



Image



## **Cosentyx® (secukinumab): Digital dosing schedule**

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related

arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.<sup>1</sup>

[Full indications for Cosentyx can be found here](#)

[Cosentyx Summary of Product Characteristics \(SmPC\) can be found here.](#)

---

Help your newly initiated Cosentyx patients keep track of their treatment with a digital dosing schedule. As a healthcare professional, you should download the relevant documents and fill in the patient's planned injection dates.

Share the completed file with your patients and they can simply tick the circles after they administer their Cosentyx dose, as shown in the example below:

Image

## Cosentyx patient dosing schedule for axSpA (ankylosing spondylitis or non-radiographic axial spondyloarthritis)

Name: **Jane Smith**

Prescribed dose: **150** mg


Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx\*, or alternatively print the document to keep track by hand.


\*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.

Your healthcare professional has already entered your planned injection dates here.



This is your last weekly dose: the injections will now be monthly.



Treatment continues once monthly. Consult your healthcare professional for further planned injection dates.

### Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Side effects may also be reported to Novartis on 01276 688370 or via [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com). By reporting side effects you can help provide more information on the safety of this medicine.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.  
COS17-C122(3) Date of preparation: July 2020



## Cosentyx patient dosing schedule for axSpA (ankylosing spondylitis or non-radiographic axial spondyloarthritis)

Name: **Jane Smith**

Prescribed dose: **150** mg


Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx\*, or alternatively print the document to keep track by hand.


\*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.

Your healthcare professional has already entered your planned injection dates here.



This is your last weekly dose: the injections will now be monthly.



Treatment continues once monthly. Consult your healthcare professional for further planned injection dates.

### Reporting of side effects



If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Side effects may also be reported to Novartis on 01276 688370 or via [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com). By reporting side effects you can help provide more information on the safety of this medicine.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.  
COS17-C122(3) Date of preparation: July 2020

**Do not share links to this website or screenshots with patients**

as this website is intended for healthcare professionals only.

## Image



### Cosentyx patient dosing schedule for Psoriatic Arthritis

Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx<sup>®</sup>, or alternatively print the document to keep track by hand.

\*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.

Your healthcare professional has already entered your planned injection dates here.

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

Week 0 1 2 3 4

Month 1

This is your last weekly dose, the injections will now be monthly.

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

Month 7 Month 6 Month 5 Month 4 Month 3 Month 2

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

dd/mm/yy

Month 8 Month 9 Month 10 Month 11 Month 12

Treatment continues once monthly. Consult your healthcare professional for further planned injection dates.

**Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Side effects may also be reported to Novartis on 01276 660370 or via [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com). By reporting side effects you can help provide more information on the safety of this medicine.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd. 262776 Date of preparation: December 2022

## Digital dosing schedule - PsA

PDF

[Download](#)

Image

**Cosentyx (secukinumab) 2 weekly dosing schedule for adult patients with psoriatic arthritis and concomitant plaque psoriasis with a body weight of 90 kg or higher**


Name:

Prescribed dose:

Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx®, or alternatively print the document to keep track by hand.  
\*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.



#### Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at [www.medicines.gov.uk/uknocard](http://www.medicines.gov.uk/uknocard). By reporting side effects, you can help provide more information on the safety of this medicine.

This resource is only intended for adult patients in the UK with plaque psoriasis with a body weight of 90 kg or higher prescribed Cosentyx. Not for further distribution.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.  
UK 1 March 2020 / 25044

## Digital dosing schedule - PsA Q2W

PDF

[Download](#)

Image

## Cosentyx patient dosing schedule for axSpA (ankylosing spondylitis or non-radiographic axial spondyloarthritis)

Name:

Prescribed dose:


Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx\*, or alternatively print the document to keep track by hand.

\*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.

Your healthcare professional has already entered your planned injection dates here.



This is your last weekly dose; the injections will now be monthly.



Treatment continues once monthly. Consult your healthcare professional for further planned injection dates.

### Reporting of side effects

If you get any side effects, tell your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at [www.medicines.gov.uk/yellowcard](http://www.medicines.gov.uk/yellowcard). Side effects may also be reported to Novartis on 01273 834120 or [uk.medic@novartis.com](mailto:uk.medic@novartis.com).

By reporting side effects you can help provide more information on the safety of this medicine.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.  
220777 Date of preparation: December 2022

## Digital dosing schedule - axSpA

PDF

[Download](#)

Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.

Image

Dosing



---

For more information on Cosentyx dosing, please see [dosing and product information](#).

### **Therapeutic Indications<sup>1</sup>**

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to

conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.<sup>1</sup>

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; HS, hidradenitis suppurativa; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; Q2W, every 2 weeks.

## Reference

1. Cosentyx® (secukinumab) Summary of Product Characteristics.

UK | March 2025 | FA-11357107

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

## Source URL:

<https://www.pro.novartis.com/uk-en/medicines/rheumatology/cosentyx/resources/dosing-schedule>